Coherus BioSciences (CHRS) Tops Q3 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.02 +2.00%
EPS Growth %: +39.4%
Financial Fact:
Selling, general, and administrative expenses: 137.78M
Today's EPS Names:
FNLC, LSBK, OVLY, More
EPS Growth %: +39.4%
Financial Fact:
Selling, general, and administrative expenses: 137.78M
Today's EPS Names:
FNLC, LSBK, OVLY, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($0.01), $0.15 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $70.77 million versus the consensus estimate of $58.98 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pharming Group N.V. (PHAR) Reports Q3 results; offers guidance
- Unicredit SpA (UCG:IM) (UNCFF) PT Raised to EUR102.60 at Barclays
- JPMorgan Downgrades Opmobility SE (OPM:FP) to Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
